ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle- Income Countries
ReiThera and Exothera Collaborate to Develop Large-scale, Low Cost per Dose Manufacturing Process to Deliver Novel Vaccines to Low- and Middle- Income Countries Collaboration awarded €3 million [...]
ReiThera’s project has been approved, in response to the Lazio Region Public Notice “Digital Diagnostic Voucher”
With the public notice “Contributions for the support of digitalization processes of companies in the Lazio region – Digital Diagnostic Voucher”, the Lazio Region intends [...]
Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
Originally published on npj Vaccines volume 6, Article number: 131 (2021). Chiara Agrati, Stefania Capone, Concetta Castilletti, Eleonora Cimini, Giulia Matusali, Silvia Meschi, Eleonora [...]
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults
Originally published on Sci Transl Med. 2021 Oct 26. doi: 10.1126/scitranslmed. abj1996.
Originally published on Molecular Therapy Volume 29, Issue 8, 4 August 2021, Pages 2412-2423 Stefania Capone, Angelo Raggioli, Michela Gentile, Simone Battella, Armin Lahm, Andrea Sommella, [...]
Originally published on Science. 2021 Jan 29;371(6528):521-526. doi:10.1126/science.aax8819.PMID: 33510029. Capone S, Brown A, Hartnell F, Sorbo MD, Traboni C, Vassilev V, Colloca S, Nicosia A, [...]
A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C
Originally published on PLoS neglected tropical diseases. 2020 Jul 15. 14(7): e0008459. doi: 10.1371/ journal. pntd.0008459.
Program funded by the Bill & Melinda Gates Foundation will use ReiThera’s GRAd platform technology to develop next generation vaccines against SARS-CoV-2 emerging variants and HIV ROME, [...]